CD4 News and Research

RSS

Study reveals multiple characteristics of HIV-1-producing cells in vivo

For eradication of HIV-1 infection, it is important to elucidate the detailed features and heterogeneity of HIV-1-infected cells in vivo.

29 Jul 2020

Ebola survivors have long-lasting severe immune dysfunction

In the 2013-2016 Ebola outbreak in West Africa, more than 28,000 people were infected, causing over 11,000 deaths.

27 Jul 2020

Study shows how protective T cells become pathogenic in atherosclerosis

High cholesterol kills. In fact, one in four Americans will die from the consequences of atherosclerosis, the buildup of plaques of fat and cholesterol in the arteries. Statins have helped reduce mortality, but millions are still at risk.

24 Jul 2020

Study points to an important role for white blood cells in brain development

Whether white blood cells can be found in the brain has been controversial, and what they might be doing used to be complete mystery.

22 Jul 2020

Vitamin D could help suppress excessive T cell-mediated lung inflammation in severe COVID-19

As COVID-19 continues to spread over the world scientists continue to seek the reasons for the difference in disease severity from person to person.

22 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

Groundbreaking technology could enhance therapeutic efficiency of nanomedicines

Researchers from the Moscow Institute of Physics and Technology and their colleagues from Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and Prokhorov General Physics Institute of the Russian Academy of Sciences have developed a breakthrough technology to resolve a key problem that has prevented the introduction of novel drugs into clinical practice for decades.

17 Jul 2020

New immune profiles could help predict disease trajectory in severe COVID-19 patients

Researchers from the Penn Institute of Immunology discovered three distinct immune responses to the SARS-CoV2 infection that could help predict the trajectory of disease in severe COVID-19 patients and may ultimately inform how to best treat them.

15 Jul 2020

Moderna vaccine induces robust immune response against SARS-CoV-2

The race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on, and one of the potential candidates shows promise in inducing an immune response.

15 Jul 2020

A new measles-based COVID-19 vaccine

Now, a new study by researchers from Germany's Paul Ehrlich Institute and published on the preprint server bioRxiv in July 2020 describes a potential vaccine based on the measles vaccine, which elicits both an antibody response and cellular immunity against the virus. This also protects against the measles virus. This could be a significant weapon in the fight against these two threats.

14 Jul 2020

Altimmune announces positive preclinical results of intranasal COVID-19 vaccine candidate

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.

13 Jul 2020

Dysfunctional T cells present at high levels in severe COVID-19

Now, a new study by researchers at Saarland University, Germany, and published on the preprint server medRxiv in July 2020 shows that there are higher levels of anti-SARS-CoV-2 T cells, which show significant alterations in the phenotype and function.

12 Jul 2020

Faulty immune response to SARS-CoV-2 one of the main causes of death

A new study published on the preprint server medRxiv in July 2020 describes the organ and tissue-specific spread of the virus causing the current COVID-19 pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 Jul 2020

Researchers find possible cause for SARS-CoV-2 reactive T cells in uninfected individuals

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) -2, leading to severe pneumonia, acute respiratory distress syndrome, and death in a sizable minority of cases. However, the most significant number are asymptomatic or have only mild infection from which they rapidly recover.

2 Jul 2020

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

Important new findings on T cell immunity in COVID-19

Researchers at the Karolinska University Hospital and University Hospital of Wales report that people who have recovered from asymptomatic or mild cases of coronavirus disease 2019 (COVID-19) may have long-term T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Jul 2020

Novel vaccine that removes aged immune cells mitigates metabolic disorders in obese mice

Aging is a multifaceted process that affects our bodies in many ways. In a new study, researchers from Osaka University developed a novel vaccine that removes aged immune cells and then demonstrated an improvement of diabetes-associated metabolic derangements by vaccinating obese mice.

30 Jun 2020

Modified Vaccinia Ankara-based vaccine candidate for SARS-CoV-2

Now, a new study by researchers at Emory University, the University of Texas Medical Branch and the Ragon Institute and published on the preprint server bioRxiv in June 2020 reports the development of a promising new vaccine candidate that may rapidly and effectively induce the production of neutralizing antibodies against the spike protein of the virus.

30 Jun 2020

COVID-19 patients can rapidly generate virus-attacking T cells, shows study

Patients suffering from severe respiratory symptoms as a result of SARS-CoV-2 infection can rapidly generate virus-attacking T cells, and can increase this production over time, suggests a new study of T cells from 10 COVID-19 patients under intensive care treatment.

27 Jun 2020

Dysregulated inflammation in severe COVID-19

The continuing COVID-19 pandemic has so far caused 9.58 million cases and more than 488,000 deaths within just six months. The spectrum of disease is broad, from completely asymptomatic cases to critical illness ending in death. Now, a new paper by researchers from Yale University and published on the preprint server medRxiv* in June 2020 identifies an imbalance in immunological response that is linked to poor outcomes and early biomarkers that may help predict the course of the disease.

25 Jun 2020